A case report of LAI two injection start in a 16-year-old adolescent with severe manic episode and comorbid cannabinoid use disorder.

There is a lack of randomized clinical trials and few studies regarding long-acting injectable antipsychotics (LAIs) in adolescents. Non-adherence, aggressiveness, comorbid substance use disorder and lack of insight may represent the main reasons for starting LAIs. Hereby we describe a 16-year-old male adolescent subject with bipolar type I disorder and comorbid cannabinoid use disorder, successfully treated with two-injection start regimen of LAI aripiprazole. Two-injection start regime of aripiprazole could represent an effective and safe therapeutic option for adolescents with early onset bipolar disorder. • There is a lack of randomized clinical trials regarding LAIs in adolescents. • LAIs display good effectiveness and acceptable tolerability in adolescents with schizophrenia and bipolar disorder. • Non-adherence, aggressiveness, comorbid substance use disorder and lack of insight could benefit from LAIs. • Aripiprazole two-injection start could be an effective and safe therapeutic option for adolescents with bipolar disorder. [ABSTRACT FROM AUTHOR]